The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 02, 2007
Filed:
Aug. 02, 2001
Joerg Meyer, Heusenstamm, DE;
Berthold Nies, Fraenkisch-Crumbach, DE;
Michel Dard, Seeheim-Jugenheim, DE;
Guenter Hoelzemann, Seeheim-Jugenheim, DE;
Horst Kessler, Schwalbach, DE;
Martin Kantlehner, Freising, DE;
Ulrich Hersel, Erlabrunn, DE;
Christoph Gibson, Ihringen, DE;
Gabor Sulyok, Munich, DE;
Joerg Meyer, Heusenstamm, DE;
Berthold Nies, Fraenkisch-Crumbach, DE;
Michel Dard, Seeheim-Jugenheim, DE;
Guenter Hoelzemann, Seeheim-Jugenheim, DE;
Horst Kessler, Schwalbach, DE;
Martin Kantlehner, Freising, DE;
Ulrich Hersel, Erlabrunn, DE;
Christoph Gibson, Ihringen, DE;
Gabor Sulyok, Munich, DE;
Biomet Deutschland GmbH, Berlin, DE;
Abstract
The invention relates to compounds of formula (I) B-Q-X, wherein B is a bioactive, cell adhesive mediating molecule, selected from the group (i) and Thr-Trp-Tyr-Lys-Ile-Ala-Phe-Gln-Arg-Asn-Arg-Lys (SEQ ID NO: 1) (ii), Trp-Tyr-Lys-Ile-Ala-Phe-Gln-Arg-Asn-Arg-Lys (SEQ ID NO: 2) (iii), Tyr-Lys-Ile-Ala-Phe-Gln-Arg-Asn-Arg-Lys (SEQ ID NO: 3) (iv), Thr-Trp-Tyr-Lys-Ile-Ala-Phe-Gln-Arg-Asn-Arg (SEQ ID NO: 4) (v), Thr-Trp-Tyr-Lys-Ile-Ala-Phe-Gln-Arg-Asn (SEQ ID NO: 5) (vi), Thr-Trp-Tyr-Lys-Ile-Ala-Phe-Gln-Arg (SEQ ID NO: 6) (vii), wherein (i) X, Y, Z, R, R, R, A, Ar, Hal, Het, Het, n, m, o, p, q, s, t have the meanings cited in claim, Q is absent or is an organic spacer molecule, Xis an anchor molecule selected from the group cited in claim, and the salts thereof, which can be used as integrin inhibitors particularly for treatment of illness, deficiencies and inflammations caused by implants and osteolytic illnesses such as osteoporosis, thrombosis, cardiac infarction and arteriosclerosis, in addition to the acceleration and strengthening of the integration process of implants or the biocompatible surface in tissue.